JAKARTA. PT Bundamedik Tbk (BMHS), the managing company of Bundar Hospital network and several diagnostic laboratories, booked net profit of IDR 10.87 billion in the first quarter of 2024.

BMHS's net profit in Q1 2024 shifted 9.25% year-on-year (yoy). For the record, the company only scored IDR 9.95 billion of net profit in Q1 2023. 

Ivan Rizal Sini, President Commissioner of BMHS, said that the company's performance at the beginning of this year will be the foundation to realize several key initiatives to improve holistic healthcare ecosystem for the public. "With this improved performance, our focus to grow sustainably across all of the ecosystems of BHMS Group will continue to take place," he said in the official statement.

From the top-line, BMHS's net profit also reported growth of 7.35% yoy to IDR 413.75 billion. This growth is supported by the number of inpatients and outpatients that rose 18% and 39% yoy. 

In addition, the number of non-COVID laboratory tests held by Diagnos, one of BMHS's business lines, also grew 43% yoy in Q1 2024. In Vitro Fertilisation (IVF) demand also reportedly increased 10% in Q1 2024 from Q4 2023. 

"With a series of strategies and thorough transformation, the ecosystem of BHMS Group is committed to continue growing alongside the changes in Indonesian's healthcare needs from time to time," Rizal Sini added. (KR/ZH)